A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Trial Profile

A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Olipudase alfa (Primary)
  • Indications Niemann-Pick disease type B
  • Focus Adverse reactions
  • Sponsors Sanofi; Sanofi Genzyme
  • Most Recent Events

    • 03 Mar 2017 Planned End Date changed from 1 Aug 2021 to 1 Oct 2021.
    • 03 Mar 2017 Planned primary completion date changed from 1 Aug 2021 to 1 Oct 2021.
    • 04 May 2016 Minimum age of subjects is changed fro 18 years to 1 year
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top